BPMC.Blueprint Medicines CORP

Form 4: Blueprint Medicines CFO Michael Landsittel Sells Shares Under 10b5-1 Trading Plan

Sentiment:

SEC Form 4 Filing

📋All filings for Blueprint Medicines CORP
🔒Login to Follow

Michael Landsittel, CFO of Blueprint Medicines, sold a portion of his company shares on May 15, 2024, under a pre-arranged trading plan.

Summary

  • On May 15, 2024, Michael Landsittel, the Chief Financial Officer of Blueprint Medicines Corp, sold shares of common stock.
  • The sales were executed under a pre-arranged trading plan adopted on December 6, 2023, in accordance with Rule 10b5-1.
  • A total of 3,850 shares were sold in two separate transactions at weighted average prices of $107.17 and $106.56.
  • Following the transactions, Landsittel directly owns 71,617 shares of Blueprint Medicines Corp.
  • The sales were conducted in multiple transactions with prices ranging from $106.23 to $107.88 per share.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock sales by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

  • The sale of shares by a high-ranking executive could be perceived negatively by some investors, potentially leading to slight downward pressure on the stock price.

Key Dates

DateDescription
12/06/2023Date of adoption of the Rule 10b5-1 trading plan.
05/15/2024Date of the reported stock sales.
05/17/2024Date of signature of the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.